A common pitfall for founders transitioning from a PhD is creating pitch decks that are essentially scientific presentations. Investors are less interested in how the technology works and more interested in the magnitude of the problem it solves and the market's demand for that solution. The 'what' and 'why' trump the 'how'.
Manufacturing induced pluripotent stem cells (iPSCs) is a highly manual, 'artisanal process' dependent on the subjective skill of individual scientists. This 'magic hands' bottleneck is a major barrier to scaling personalized therapies. Cellino's strategy is to automate these steps with AI and lasers to solve this core challenge.
The FDA's Advanced Manufacturing Technology designation, which Cellino received, challenges the belief that the agency is indifferent to manufacturing scale and cost. This program signals that regulators recognize manufacturing as a key bottleneck for patient access and are now collaborating with developers to accelerate scalable solutions.
Startups born from PhD research often begin with a technology and must then find its most valuable application, the reverse of identifying a market need first. This makes extensive customer discovery critical to validate demand and pivot from the initial academic focus, as Cellino's founder experienced firsthand.
The company’s PhD research focused on using lasers for precise intracellular cargo delivery. However, conversations with 100+ industry experts revealed a more critical, and technically simpler, problem in cell therapy manufacturing: removing unwanted cells. This demonstrates the value of prioritizing market needs over scientific complexity.
The ideal future for personalized cell therapies involves decentralized manufacturing using mobile units at the point of care, like a hospital. This model, which Cellino is pioneering with Mass General Hospital, eliminates complex logistics, reduces costs, and broadens patient access beyond major urban centers to rural areas.
The first iPSC therapies focused on CNS and eye diseases not because they were the biggest markets, but because their differentiation protocols were discovered first—sometimes by accident, like leaving cells in an incubator over Christmas break. This shows how scientific serendipity, not strategy, can shape a field's initial direction.
Marinna Madrid, trained in both fields, observes that physics is a mature, slow-moving discipline with discoveries every 30-40 years. In contrast, biology is rife with unknowns, leading to major published discoveries almost daily. This rapid pace and vast mystery create a more fertile ground for new companies and applications.